ArticleEndocrine connections2025
Long-term efficacy of dapagliflozin combined with Bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight/obese patients with type 2 diabetes.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising global prevalence of type 2 diabetes (T2D) necessitates innovative therapies targeting glycemic control and metabolic complications. SGLT2 inhibitors improve cardiorenal outcomes and may modulate gut microbiota, while specific probiotics demonstrate glycemic and lipid benefits. However, synergistic effects of combining SGLT2 inhibitors with probiotics remain unexplored. Methods: This 24-week randomized controlled trial enrolled 120 overweight/obese T2D patients (BMI ≥ 24 kg/m2, HbA1c ≥ 7.0%). Participants were randomized to dapagliflozin (10 mg/day) alone (control, n = 60) or dapagliflozin plus triple viable tablets, containing Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis (six tablets/day, ≥1.0 × 107 CFU/g/strain; experimental, n = 60). The primary outcome was HbA1c change; secondary outcomes included weight, lipid profiles, blood pressure, gut microbiota (qPCR quantification), and safety. Analyses used mixed-effects models (completers: 57 control, 58 experimental) and Spearman correlations. Results: The experimental group showed superior improvements in weight (-5.2 kg vs -3.1 kg), HbA1c (-1.8% vs -0.8%), LDL-C (-0.5 vs -0.3 mmol/L), HDL-C (+0.17 vs +0.07 mmol/L), and HOMA-IR (-1.2 vs -0.6) compared to controls (all P < 0.05). Gut microbiota analysis revealed increased Bifidobacterium (7.3 vs 5.5 log CFU/g, P < 0.001), reduced Enterobacteriaceae (4.5 vs 6.5 log CFU/g, P = 0.003), and a higher gram-positive/negative ratio (1.12 vs 0.70, P = 0.001). Bifidobacterium abundance correlated with HbA1c reduction (r = -0.42, P = 0.008), while gram-positive/negative ratio was linked to improved HDL-C (r = 0.26, P = 0.041). Adverse events were comparable between groups (28.3 vs 25.0%, P = 0.672). Conclusions: Combining dapagliflozin with Bifidobacterium probiotics enhances metabolic outcomes and favorably modulates gut microbiota in T2D patients. These findings support microbiota-targeted adjunctive therapy to optimize SGLT2 inhibitor efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.